Influence of Magnesium on Blood Pressure and the Effect of Nifedipine in Rats

AXEL OVERLACK, JOHANNES G. ZENZEN, CHRISTA Ressel, HANS M. MÜLLER, AND KLAUS O. STUMPE

SUMMARY The influence of long-term alterations in dietary magnesium intake on blood pressure and on the antihypertensive effect of the calcium antagonist nifedipine was investigated in normotensive Wistar-Kyoto (WKY) and in spontaneously hypertensive rats (SHR). The rats were fed a diet either high (1%), normal (0.1%), or low (0.01%) in magnesium for 12 weeks (WKY) and 20 weeks (SHR), respectively. Nifedipine was added to the diet for 4 weeks in concentrations of 300 and 1000 ppm. Each dose was given for 2 weeks. Plasma and intraerythrocytic concentrations of sodium, potassium, and magnesium were measured before and at the end of nifedipine treatment. Blood was obtained by cardiac puncture. In the WKY and SHR, blood pressure was not influenced by magnesium intake. The blood pressure-lowering effect of nifedipine was most pronounced on normal dietary magnesium and was significantly suppressed in the magnesium-deficient rats. Plasma and intracellular total magnesium concentrations were consistently increased during high and reduced during low dietary intake of the ion. Intracellular sodium concentration increased during magnesium deficiency and was normalized by nifedipine. The marked and long-term alterations in plasma and intracellular concentrations of magnesium did not influence arterial blood pressure levels in either the normotensive WKY or the SHR. Therefore, dietary magnesium intake does not appear to play an important role in long-term regulation of blood pressure in rats. However, magnesium depletion attenuates the blood pressure-lowering effect of nifedipine. (Hypertension 9: 139-143, 1987)

KEY WORDS • magnesium • nifedipine • intracellular electrolytes • hypertension • spontaneously hypertensive rats

It has been suggested that the divalent cation magnesium plays an important role in the regulation of blood pressure. This suggestion is based on the observation that magnesium depletion enhances vascular reactivity to vasoconstrictor agents and that it may accelerate cardiovascular disease. In contrast, magnesium excess stabilizes vascular membranes and reduces vascular tone. An inverse relationship between intracellular free magnesium and systolic and diastolic blood pressure has been reported. Epidemiological data suggest that a diet rich in magnesium may protect against cardiovascular events. However, the available data on the long-term importance of magnesium for blood pressure regulation in human and experimental hypertension are limited and controversial.

In normotensive rats blood pressure has been reported to be reduced during magnesium deficiency. In spontaneously hypertensive rats (SHR), high dietary magnesium intake has been found to lower blood pressure. However, Günther et al. did not observe a relation between the development of hypertension and magnesium intake in SHR. In essential hypertension, a diet rich in magnesium appears to enhance the antihypertensive effect of thiazide diuretics.

Experimental evidence suggests that magnesium affects cell function and vascular tone through its effects on calcium handling. Magnesium deficiency may produce vasoconstriction by allowing excess entry and intracellular release of calcium. Magnesium appears to be a naturally occurring antagonist of calcium. Therefore, changes in intracellular or extracellular concentrations of magnesium might also affect the therapeutic efficacy of calcium entry blockers.

In the present study, the influence of long-term alterations in dietary magnesium on blood pressure and
on the antihypertensive effect of nifedipine was investigated in normotensive Wistar-Kyoto rats (WKY) and in SHR. The results suggest that dietary magnesium intake is not important in long-term blood pressure regulation but that the vasodilator effects of calcium antagonists are partly dependent on intracellular and extracellular magnesium concentrations.

Materials and Methods

Ten-week-old SHR (Okamoto-Aoki strain) and normotensive WKY were obtained from Charles River Wega (Sulzfeld, West Germany). For 2 weeks before the experiment began, all rats received a diet with a normal magnesium content, during which the animals became accustomed to the blood pressure measurements. Distilled water was given ad libitum as drinking fluid throughout the experiment. All procedures followed were in accordance with the institutional guidelines.

The WKY and SHR were subdivided into three groups each. All experimental groups consisted of eight animals. The rats were fed a diet either high (1%), normal (0.1%), or low (0.01%) in magnesium (Sniff, Soest, West Germany). Except for its concentration of magnesium, the composition of the three diets was identical. The different diets were prepared by adding monomagnesium-l-aspartate hydrochloride to a magnesium-deficient rat chow (0.01% Mg²⁺). The concentrations of magnesium in the diet were checked by atomic absorption spectrophotometry before feeding the chow to the rats. Mg-aspartate-HCl was chosen because it does not affect acid-base status, in contrast to such other magnesium salts as MgO, MgSO₄, or MgCl₂. The experimental period was 20 weeks for the SHR and 12 weeks for the WKY. From Weeks 9 to 12, the calcium antagonist nifedipine was added to the diet in concentrations of 300 and 1000 ppm. Each dose was given for 2 weeks. The daily food intake was randomly tested. The estimated intake did not differ between the experimental groups. Nifedipine was generously supplied by Bayer AG, Wuppertal, West Germany.

Body weight and systolic blood pressure were measured weekly. Systolic blood pressure was determined by a tail-cuff method in the conscious animal using a programed electrosphygmomanometer (Infraton Tensiomat FIB 4/2; Boucke, Tübingen, West Germany) and a rat holder temperature control unit (Narco-Biosystems, Houston, TX, USA).

Blood for the measurements of plasma and intracellular total concentrations of sodium, potassium, and magnesium was obtained in a heparinized syringe by cardiac puncture with the rats under light ether anesthesia at the end of Weeks 8 and 12 of the experiment. From the obtained blood, aliquots were separated for the measurements of hematocrit and hemoglobin. The remainder was centrifuged at 4000 g at 0°C for 10 minutes, and plasma and Buffy coat were removed. In plasma, concentrations of sodium and potassium were determined by flame photometry. The plasma concentrations of magnesium and the intracellular concentrations of sodium, potassium, and magnesium were measured by atomic absorption spectrophotometry (Model 2280; Perkin Elmer, Norwalk, CT, USA) as previously described by Duhm and Göbel. In brief, four aliquots of packed red blood cells (100 µl) were washed three times in 2 ml of a solution containing 150 mmol choline chloride, 10 mmol Tris morpholinepropanesulfonic acid, 5 mmol dextrose, and 1 mmol phosphoric acid, pH 7.4, at 37°C. The suspensions were centrifuged at 4000 g for 4 minutes. The packed red blood cells were hemolyzed with 1.6 ml of 6% 1-butanol and stored at 4°C until the measurements of intracellular concentrations of sodium, potassium, and magnesium were performed. Hemoglobin was determined in the hemolysates as cyanohemoglobin. The red blood cell cation contents were calculated from hemoglobin and cation concentrations in the lysates on the basis of the mean cellular hemoglobin content as determined in the fresh blood. Measurements were done in triplicate. Intracellular electrolyte concentrations were given as millimoles per liter of cells.

Statistical analysis was performed by analysis of variance and by Student's t test for paired and unpaired data. A p value below 0.05 was considered significant.

All values are given as the mean ± SEM.

Results

In the normotensive WKY, systolic blood pressure was not influenced by either high or low magnesium intakes as compared with normal dietary magnesium (Figure 1). Nifedipine in a dietary concentration of 300 ppm lowered blood pressure significantly during normal magnesium intake. The higher dose of nifedipine (1000 ppm) had no additional effect. In the normotensive rats receiving a low or high magnesium intake, blood pressure was reduced only slightly by nifedipine (Figure 1). In the SHR, blood pressure was not influenced by the different dietary intakes of magnesium but fell significantly in all groups of rats when nifedipine, 300 ppm, was given (Figure 2). The effect of the calcium antagonist was slightly enhanced by increasing the dose to 1000 ppm. The response to nifedipine was most pronounced in the rats on normal magnesium intake. The blood pressure-lowering effect of nifedipine was significantly blunted during low dietary magnesium. After withdrawal of nifedipine, blood pressure rose to pretherapeutic levels in all groups.

The increase in body weight during the observation period was comparable in all groups and was not influenced by the concentration of magnesium in the diet (Table 1). Plasma concentrations of sodium and potassium were within the normal range in all dietary groups and were not altered by nifedipine (Table 2). As compared with normal magnesium intake (0.1%), the plasma concentrations of magnesium were significantly reduced during low and significantly increased during high magnesium intake in both the SHR and WKY (see Table 2).

Regardless of magnesium intake, intracellular sodi-
MAGNESIUM AND BLOOD PRESSURE REGULATION/Over/et al. 141

Figure 1. Systolic blood pressure in normotensive WKY during high (1%), normal (0.1%), and low (0.01%) magnesium intake and during administration of nifedipine. Asterisk indicates significant (p<0.05) differences in blood pressure compared with normal magnesium intake. Dagger indicates significant (p<0.05) nifedipine-induced changes in blood pressure.

Discussion
In the present study, the influence of long-term alterations in dietary magnesium on blood pressure was investigated in normotensive WKY and SHR. Neither magnesium deficiency nor a diet high in magnesium appeared to influence blood pressure significantly. As early as 1925 it was suggested that magnesium salts might be of value in the treatment of hypertension. Intra-arterial infusions of magnesium salts provoke an acute vasodilator response and attenuate the pressor effect of vasoconstrictor agents. The therapeutic efficacy of magnesium in eclamptic women is widely recognized and used. Magnesium appears to enhance the antihypertensive effect of diuretics, an effect that may be due to correction of diuretic-induced...

Table 1. Body Weight During Different Magnesium Intakes in SHR and Normotensive WKY

<table>
<thead>
<tr>
<th>Diet</th>
<th>Control</th>
<th>Week 8</th>
<th>Week 12</th>
<th>Week 20</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01% Mg</td>
<td>211±2</td>
<td>291±4</td>
<td>314±6</td>
<td>331±15</td>
</tr>
<tr>
<td>0.1% Mg</td>
<td>214±3</td>
<td>306±4</td>
<td>330±6</td>
<td>362±7</td>
</tr>
<tr>
<td>1% Mg</td>
<td>210±4</td>
<td>282±2</td>
<td>312±4</td>
<td>347±4</td>
</tr>
<tr>
<td>WKY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01% Mg</td>
<td>211±5</td>
<td>304±5</td>
<td>329±5</td>
<td></td>
</tr>
<tr>
<td>0.1% Mg</td>
<td>211±4</td>
<td>311±2</td>
<td>325±3</td>
<td></td>
</tr>
<tr>
<td>1% Mg</td>
<td>218±3</td>
<td>317±5</td>
<td>341±6</td>
<td></td>
</tr>
</tbody>
</table>

Values are means ± SEM.

Table 2. Plasma Electrolyte Concentrations After 8 Weeks of Different Magnesium Intakes and After an Additional 4 Weeks of Treatment with Nifedipine in SHR and Normotensive WKY

<table>
<thead>
<tr>
<th>Diet</th>
<th>Week</th>
<th>Sodium (mmol/L)</th>
<th>Potassium (mmol/L)</th>
<th>Magnesium (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01% Mg</td>
<td>8</td>
<td>142.8±0.6</td>
<td>4.3±0.1</td>
<td>0.16±0.07*</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>141.6±0.6</td>
<td>4.0±0.1</td>
<td>0.23±0.03*</td>
</tr>
<tr>
<td>0.1% Mg</td>
<td>8</td>
<td>143.3±0.4</td>
<td>3.9±0.1</td>
<td>0.78±0.01</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>143.3±0.5</td>
<td>4.1±0.1</td>
<td>0.70±0.09</td>
</tr>
<tr>
<td>1% Mg</td>
<td>8</td>
<td>140.5±0.6</td>
<td>4.2±0.1</td>
<td>1.82±0.09*</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>140.5±0.6</td>
<td>4.0±0.1</td>
<td>1.72±0.03*</td>
</tr>
<tr>
<td>WKY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01% Mg</td>
<td>8</td>
<td>142.0±0.2</td>
<td>4.2±0.1</td>
<td>0.14±0.01*</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>141.0±0.4</td>
<td>3.9±0.1</td>
<td>0.29±0.02*</td>
</tr>
<tr>
<td>0.1% Mg</td>
<td>8</td>
<td>141.3±0.6</td>
<td>4.4±0.1</td>
<td>0.78±0.03</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>143.4±0.9</td>
<td>4.2±0.1</td>
<td>0.77±0.02</td>
</tr>
<tr>
<td>1% Mg</td>
<td>8</td>
<td>141.6±0.5</td>
<td>4.2±0.1</td>
<td>1.68±0.05*</td>
</tr>
<tr>
<td></td>
<td>12</td>
<td>139.5±0.7</td>
<td>4.0±0.1</td>
<td>1.70±0.04*</td>
</tr>
</tbody>
</table>

Values are means ± SEM.
*p < 0.001, compared with normal magnesium intake (0.1% Mg).
hypomagnesemia. The rates of vascular disease seem
to be lower in hard water areas than in soft water
areas, an observation that has been partially ascribed
to higher ingestion of magnesium. Whether magne-
sium intake is related to blood pressure in humans is
controversial. No data are available on the influ-
cence of long-term dietary supplementation of magne-
sium in human hypertension. The results obtained in
laboratory animals, mainly rats, are contradictory. In
normotensive rats, blood pressure has been reported to
be reduced during magnesium deficiency. It has been postulated
that the influence of magne-
sium on vascular smooth muscle is related to its influ-
ence on intracellular calcium metabolism. Magnes-
ium is an antagonist of calcium entry into the cell. Thus, the antihy-
gerensive action of calcium antagonists may be al-
tered by changes in dietary magnesium intake with
subsequent changes in intracellular magnesium con-
tent. This hypothesis is supported by the findings of

In contrast to intracellular total magnesium, intra-
cellular sodium and potassium concentrations both
were significantly higher in the hypertensive animals.
Dietary magnesium deficiency increased intracellular
sodium in the SHR and WKY and may have been due
to an inhibition of Na⁺,K⁺-adenosine triphosphatase
during magnesium deficiency. It has been postulated
that an increase in intracellular sodium may give rise to
an increase in intracellular calcium concentration and
thereby increase blood pressure. In the present study,
however, blood pressure did not increase during
magnesium deficiency despite a significant rise in
intracellular sodium concentration. Administration of
the calcium antagonist nifedipine lowered intracel-
lar sodium in the magnesium-deficient and the mag-
nesium-supplemented rats. Calcium antagonists are
thought to lower peripheral vascular resistance by re-
ducing the free calcium concentration in smooth mus-
cle cells. Gray et al. observed that verapamil could
reduce a defect in sodium transport in leukocytes in
essential hypertension. They concluded that a reduced
intracellular calcium content brought about by a cal-
lum antagonist may increase the sodium efflux rate
constant. This effect could explain the reduction in
intracellular sodium concentration during treatment
with nifedipine observed in the present study.

It has been proposed that the influence of magne-
sium on vascular smooth muscle is related to its influ-
ce on intracellular calcium metabolism. Magnes-
ium is an antagonist of calcium entry into the cell. Fur-
thermore, magnesium may antagonize calcium
binding at intracellular sites, stimulate calcium influx
into the sarcoplasmic reticulum, and retard calcium
efflux into the extracellular space. Thus, the antihy-
pertensive action of calcium antagonists may be al-
tered by changes in dietary magnesium intake with
subsequent changes in intracellular magnesium con-
tent. This hypothesis is supported by the findings of

| Table 3. Intracellular Electrolyte Concentrations After 8 Weeks of Different Magnesium Intakes and After an Addi-
<table>
<thead>
<tr>
<th>tional 4 Weeks of Treatment with Nifedipine in SHR and Normotensive WKY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diet</strong></td>
</tr>
<tr>
<td><strong>Week</strong></td>
</tr>
<tr>
<td>SHR</td>
</tr>
<tr>
<td>0.01% Mg</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>0.1% Mg</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>1% Mg</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>WKY</td>
</tr>
<tr>
<td>0.01% Mg</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>0.1% Mg</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>1% Mg</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Values are means ± SEM. *p < 0.001, †p < 0.01, §p < 0.05, compared with normal magnesium intake (0.1% Mg).
*p < 0.001, †p < 0.01, §p < 0.05, compared with Week 8 value.
#p < 0.001, compared with value for WKY.
Phillips and Robinson, 23 who observed an enhanced vasodilator response to verapamil in essential hypertension when magnesium was infused intra-arterially, whereas calcium infusions attenuated the effect of the calcium antagonist. In the present study, the blood pressure–lowering effect of nifedipine was significantly reduced during magnesium deficiency. The profound suppression of intracellular magnesium content during dietary magnesium depletion may have increased intracellular calcium concentration and altered calcium distribution within the cell. Therefore, the attenuated response to nifedipine during magnesium deficiency may be a consequence of changes in intracellular calcium activity. However, this explanation remains hypothetical, since intracellular and extracellular levels of total and ionized calcium were not determined in the present study.

In conclusion, even profound and long-term alterations in plasma and intracellular concentrations of total magnesium did not influence arterial blood pressure levels in either the normotensive WKY or the SHR. Therefore, dietary magnesium intake does not appear to play an important role in long-term regulation of blood pressure in rats. However, magnesium depletion attenuates the blood pressure–lowering effect of the calcium antagonist nifedipine.

References

Influence of magnesium on blood pressure and the effect of nifedipine in rats.
A Overlack, J G Zenzen, C Ressel, H M Müller and K O Stumpe

Hypertension. 1987;9:139-143
doi: 10.1161/01.HYP.9.2.139

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1987 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/9/2/139

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org/subscriptions/